Kliniska studier vid Tema Cancer

Labmarkörer MPN-patienter . Labmarkörer som en del av riskbedömning för trombohemorrhagiska komplikationer hos patienter med myeloproliferativa sjukdomar

Roza Chaireti

MAATEO. A phase 1 study in MDS, AML and ALL patients to evaluate safety, tolerability and efficacy of Karonudib

Stefan Deneberg

HOVON 150. A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acutemyeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy

Martin Jädersten

EVI-3: Combining Active and Passive DNA Hypomethylation. EVI-3: Combining Active and Passive DNA Hypomethylation A multicenter, randomized, parallel-group, placebo-controlled phase II study of the efficacy and safety of oral vitamin C supplement in combination with azacitidine in higher-risk MDS, CMML, and low-blast-count AML

Eva Hellström Lindberg

LD-VenEx. LD-VenEx Clinical Study Protocol: Phase 2 study of azacitidine in combination with low dose intensity venetoclax in patients with acute myeloid leukemia with integration of explorative multi-omics and ex vivo drug screening data

Martin Jädersten

MK3543-007 (Shorespan-007). A phase 3, Randomized, Double-blind, Active.Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK3543) versus Hydroxyurea in Cytoreductive Therapy Naive Essential thrombocythemia Partiocipants

Anna Ravn Landtblom

RENEW-KER-050-D301. A Phase 3, Randomized, Double-blind, Placebo-Controlled Study toEvaluate the Efficacy and Safety of Elritercept in Adult Participantswith Very Low, Low, or Intermediate Risk MyelodysplasticSyndromes (MDS) with Anemia

Magnus Tobiasson

Lumina 3. A phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA)

Cecilia Karlström

Immunologiska lab-studier på patienter med KLL och andra hematol. In vitro studier av immunologiska funktioner hos patienter med kroniska lymfoproliferativa tumörsjukdomar (Myelom, lymfom, KLL) och MGOS: Extra blodprovstagning

Anders Österborg

BioLymph. Prospektiv studie av biologi, etiologi och överlevnad vid lymfom (BioLymph).

Karin Ekström Smedby

PRO-Hodgkin. Clinical investigation of PBS proton treatment in Hodgkin lymphoma patients

Lotta Hansson

DSA-LL-studien. Better and individualised therapy for patients with relapsing lymphoma and leukaemia

Björn Wahlin

ALLTogether-1. ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)

Joel Joelsson

BGB3111-LTE1 Roll-overstudie. En öppen, multicenter, långsiktig förlängningsstudie av zanubrutinib (BGB-3111) hos patienter med Bcellsmaligniteter.

Björn Wahlin

BELLWAVE-011 (MK1026-011). A Phase 3, Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib as 1L+ Therapy in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

Anders Österborg

HYPERION. Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial

Björn Wahlin

SOUNDTRACK-B. A Modular Phase II, Single-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of AZD0486 in Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Björn Wahlin

NLG-FL7 FLIRT. Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FL

Björn Wahlin

BGB-11417-303. A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Lotta Hansson

BGB-16673-304. A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom

Anders Österborg

MAGNETISMM-7-studie. A randomised, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation

Katarina Uttervall

MajesTEC-7. A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy

Katarina Uttervall

ODX-MM-001. A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma

Katarina Uttervall

A-EKG-HemA. Kardiovaskulära risker och mikropartiklarnas roll i en åldrade population av patienter med hemofili A under olika behandlingsregim

Roza Chaireti

LIBERTY- Sobi.BIVV001-002 . A multinational, prospective, open-label, roll-over study (LIBERTY) to provide post-trial access to treatment for patients with severe haemophilia A who have completed a previous trial with efanesoctocog alfa

Maria Magnusson